Catherine Wei, MD
Assistant Professor of Medicine (Medical Oncology and Hematology)Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Instructor of Clinical Medicine, Hematology
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Instructor of Clinical Medicine, Hematology
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Instructor of Clinical Medicine, Hematology
Contact Info
About
Copy Link
Titles
Assistant Professor of Medicine (Medical Oncology and Hematology)
Instructor of Clinical Medicine, Hematology
Biography
Catherine Wei, MD, is an Instructor of Clinical Medicine (Hematology) and cares for patients in need of hematologic treatment and care. She received her Medical Degree from the Albert Einstein College of Medicine and completed her residency and fellowship at Rutgers University Robert Wood Johnson with a fellow elective in Bone Marrow Transplantation and Cellular erapies at Memorial Sloan Kettering Cancer Center. During her fellowship training, Dr. Wei received the Melvyn H. Motolinsky Hematology Research Foundation Award, established to support research into leukemia and other blood-related diseases. She also received the very competitive Gallo Award for Outstanding Cancer Research in 2015 from the Cancer Institute of New Jersey. Dr. Wei’s current research is focused on Burkitt Lymphoma, as well as improved use of bronchoscopy and pathological analysis for bone marrow transplant patients.
Departments & Organizations
- Hematology
- Yale Medicine
Education & Training
- MD
- Albert Einstein College of Medicine (2014)
Research
Copy Link
Overview
Medical Research Interests
Research at a Glance
Publications Timeline
Publications
2021
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.
Alderuccio JP, Olszewski AJ, Evens AM, Collins GP, Danilov AV, Bower M, Jagadeesh D, Zhu C, Sperling A, Kim SH, Vaca R, Wei C, Sundaram S, Reddy N, Dalla Pria A, D'Angelo C, Farooq U, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Kassam S, Yazdy M, Rabinovich E, Post FA, Varma G, Karmali R, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Mian A, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Maliske SM, Epperla N, Caimi P, Smith SE, Kamdar M, Venugopal P, Feldman TA, Rector D, Smith SD, Stadnik A, Portell CA, Lin Y, Naik S, Montoto S, Lossos IS, Cwynarski K. HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood Advances 2021, 5: 2852-2862. PMID: 34283175, PMCID: PMC8341354, DOI: 10.1182/bloodadvances.2021004458.Peer-Reviewed Original ResearchOutcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
Zayac AS, Evens AM, Danilov A, Smith SD, Jagadeesh D, Leslie LA, Wei C, Kim SH, Naik S, Sundaram S, Reddy N, Farooq U, Kenkre VP, Epperla N, Blum KA, Khan N, Singh D, Alderuccio JP, Godara A, Yazdy MS, Diefenbach C, Rabinovich E, Varma G, Karmali R, Shao Y, Trabolsi A, Burkart M, Martin P, Stettner S, Chauhan A, Choi YK, Straker-Edwards A, Klein A, Churnetski MC, Boughan KM, Berg S, Haverkos BM, Orellana-Noia VM, D'Angelo C, Bond DA, Maliske SM, Vaca R, Magarelli G, Sperling A, Gordon MJ, David KA, Savani M, Caimi P, Kamdar M, Lunning MA, Palmisiano N, Venugopal P, Portell CA, Bachanova V, Phillips T, Lossos IS, Olszewski AJ. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica 2021, 106: 1932-1942. PMID: 33538152, PMCID: PMC8252937, DOI: 10.3324/haematol.2020.270876.Peer-Reviewed Original ResearchBurkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.
Evens AM, Danilov A, Jagadeesh D, Sperling A, Kim SH, Vaca R, Wei C, Rector D, Sundaram S, Reddy N, Lin Y, Farooq U, D'Angelo C, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Yazdy M, Rabinovich E, Varma G, Karmali R, Mian A, Savani M, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein AK, Blum KA, Boughan KM, Smith SE, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Ramdial J, Maliske SM, Epperla N, Venugopal P, Feldman TA, Smith SD, Stadnik A, David KA, Naik S, Lossos IS, Lunning MA, Caimi P, Kamdar M, Palmisiano N, Bachanova V, Portell CA, Phillips T, Olszewski AJ, Alderuccio JP. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood 2021, 137: 374-386. PMID: 32663292, PMCID: PMC8765121, DOI: 10.1182/blood.2020006926.Peer-Reviewed Original Research
2020
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy.
Carreau NA, Pail O, Armand P, Merryman R, Advani RH, Spinner MA, Herrera A, Chen R, Tomassetti S, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta S, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Godfrey J, Chavez J, Xia Y, Troxel AB, Diefenbach C. Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. The Oncologist 2020, 25: 878-885. PMID: 32720734, PMCID: PMC7543382, DOI: 10.1634/theoncologist.2020-0167.Peer-Reviewed Original ResearchImpact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.
Merryman RW, Carreau NA, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Nina Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David KA, Wei C, Lansigan F, Emery L, Persky D, Smith SM, Godfrey J, Chavez J, Cohen JB, Troxel AB, Diefenbach C, Armand P. Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. The Oncologist 2020, 25: e993-e997. PMID: 32275786, PMCID: PMC7288660, DOI: 10.1634/theoncologist.2020-0040.Peer-Reviewed Original Research
2019
CMV reactivation in allogeneic hematopoietic stem cell transplant patients receiving post-transplant cyclophosphamide.
Markowski P, Schaar D, Wei C, Tyno A. CMV reactivation in allogeneic hematopoietic stem cell transplant patients receiving post-transplant cyclophosphamide. Journal Of Clinical Oncology 2019, 37: e18533-e18533. DOI: 10.1200/jco.2019.37.15_suppl.e18533.Peer-Reviewed Original ResearchCitationsConceptsPost-transplant cyclophosphamideStem cell transplant patientsCMV reactivationCell transplant patientsPTCy groupTransplant patientsAllogeneic hematopoietic stem cell transplant patientsHematopoietic stem cell transplant patientsReactivation rateDonor CMV serostatusDonor CMV statusPost-transplant CYPrevention of graftEffective prophylactic treatmentNumber of patientsDonor serostatusTransplant cyclophosphamideCMV serostatusHost diseaseCMV statusRetrospective reviewProphylactic treatmentIncreased incidencePatient populationCMV titers
2017
An age dependent response to hydroxyurea in pediatric sickle cell anemia patients with alpha thalassemia trait.
Figueiredo L, Morrone K, Wei C, Ireland K, Cohen HW, Driscoll C, Manwani D. An age dependent response to hydroxyurea in pediatric sickle cell anemia patients with alpha thalassemia trait. Blood Cells, Molecules & Diseases 2017, 66: 19-23. PMID: 28783617, DOI: 10.1016/j.bcmd.2017.07.004.Peer-Reviewed Original ResearchLactobacillus rhamnosus GG probiotic enteric regimen does not appreciably alter the gut microbiome or provide protection against GVHD after allogeneic hematopoietic stem cell transplantation
Gorshein E, Wei C, Ambrosy S, Budney S, Vivas J, Shenkerman A, Manago J, McGrath MK, Tyno A, Lin Y, Patel V, Gharibo M, Schaar D, Jenq RR, Khiabanian H, Strair R. Lactobacillus rhamnosus GG probiotic enteric regimen does not appreciably alter the gut microbiome or provide protection against GVHD after allogeneic hematopoietic stem cell transplantation. Clinical Transplantation 2017, 31: e12947. PMID: 28256022, DOI: 10.1111/ctr.12947.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIncidence of GVHDStem cell transplantAllogeneic stem cell transplantCell transplantAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell patientsGut microbiomeHematopoietic stem cell transplantHematopoietic stem cell transplantationGut microbiome associationStem cell transplantationStem cell patientsMajor adverse effectsGut microbiome analysisHost diseaseCell transplantationCell patientsClinical trialsGVHDInterim analysisTransplantAdverse effectsAdditional studiesIncidenceProbiotic lactobacilli
Clinical Care
Copy Link
Overview
Catherine Wei, MD, specializes in hematology, treating conditions related to the blood and immune system, including anemia and white blood cell disorders.
In addition to her clinical practice, Dr. Wei’s research focuses on focuses on Burkitt Lymphoma, and she is also working to improve the process of bronchoscopy and pathological analysis for bone marrow transplant patients.
Dr. Wei is an instructor of clinical medicine at Yale School of Medicine.
Clinical Specialties
Fact Sheets
Anemia
Learn More on Yale MedicineCancer-Related Fatigue
Learn More on Yale MedicineMyeloproliferative Neoplasms
Learn More on Yale MedicineMyelodysplastic/Myeloproliferative Neoplasms
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
Copy Link
Get In Touch
Copy Link
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.